86 related articles for article (PubMed ID: 21411322)
21. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP
Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.
Kumar JS; Majo VJ; Hsiung SC; Millak MS; Liu KP; Tamir H; Prabhakaran J; Simpson NR; Van Heertum RL; Mann JJ; Parsey RV
J Med Chem; 2006 Jan; 49(1):125-34. PubMed ID: 16392798
[TBL] [Abstract][Full Text] [Related]
24. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
[TBL] [Abstract][Full Text] [Related]
25. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.
Jagoda E; Contoreggi C; Lee MJ; Kao CH; Szajek LP; Listwak S; Gold P; Chrousos G; Greiner E; Kim BM; Jacobson AE; Rice KC; Eckelman W
J Med Chem; 2003 Aug; 46(17):3559-62. PubMed ID: 12904058
[TBL] [Abstract][Full Text] [Related]
26. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
Arvanitis AG; Gilligan PJ; Chorvat RJ; Cheeseman RS; Christos TE; Bakthavatchalam R; Beck JP; Cocuzza AJ; Hobbs FW; Wilde RG; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky PJ; Rescinito JP; Scholfield E; Culp S; De Souza EB; Fitzgerald L; Grigoriadis D; Tam SW; Shen HL
J Med Chem; 1999 Mar; 42(5):805-18. PubMed ID: 10072679
[TBL] [Abstract][Full Text] [Related]
27. The three-dimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors.
Perrin MH; Grace CR; Riek R; Vale WW
Ann N Y Acad Sci; 2006 Jul; 1070():105-19. PubMed ID: 16888152
[TBL] [Abstract][Full Text] [Related]
28. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides.
Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
J Med Chem; 2004 Jun; 47(13):3450-4. PubMed ID: 15189041
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and antiamoebic activity of 3,7-dimethyl-pyrazolo[3,4-e][1,2,4] triazin-4-yl thiosemicarbazide derivatives.
Singh S; Husain K; Athar F; Azam A
Eur J Pharm Sci; 2005 Jun; 25(2-3):255-62. PubMed ID: 15911221
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of 2-[3,5-substituted pyrazol-1-yl]-4,6-trisubstituted triazine derivatives as antimalarial agents.
Katiyar SB; Srivastava K; Puri SK; Chauhan PM
Bioorg Med Chem Lett; 2005 Nov; 15(22):4957-60. PubMed ID: 16168643
[TBL] [Abstract][Full Text] [Related]
31. The most stable tautomer of 3-amino-1,2,4-triazin-5-one and its structural geometry.
Jalilian MR; Zahedi-Tabrizi M
Spectrochim Acta A Mol Biomol Spectrosc; 2008 Oct; 70(5):1020-4. PubMed ID: 18023608
[TBL] [Abstract][Full Text] [Related]
32. Two regioisomers of condensed thioheterocyclic triazine synthesized from 6-phenyl-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazin-5-one.
Hori A; Ishida Y; Kikuchi T; Miyamoto K; Sakaguchi H
Acta Crystallogr C; 2009 Dec; 65(Pt 12):o593-7. PubMed ID: 19966438
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists.
Wilcoxen K; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
Bioorg Med Chem Lett; 2003 Oct; 13(19):3367-70. PubMed ID: 12951127
[TBL] [Abstract][Full Text] [Related]
34. Efficient functionalizations of heteroatom-bridged calix[2]arene[2]triazines on the larger rim.
Yang HB; Wang DX; Wang QQ; Wang MX
J Org Chem; 2007 May; 72(10):3757-63. PubMed ID: 17425370
[TBL] [Abstract][Full Text] [Related]
35. Solid-phase synthesis of 5-substituted amino pyrazoles.
Dodd DS; Martinez RL; Kamau M; Ruan Z; Van Kirk K; Cooper CB; Hermsmeier MA; Traeger SC; Poss MA
J Comb Chem; 2005; 7(4):584-8. PubMed ID: 16004502
[TBL] [Abstract][Full Text] [Related]
36. Convenient synthesis of fused heterocyclic 1,3,5-triazines from some N-acyl imidates and heterocyclic amines as anticancer and antioxidant agents.
Bekircan O; Küxük M; Kahveci B; Kolayli S
Arch Pharm (Weinheim); 2005 Aug; 338(8):365-72. PubMed ID: 16041836
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.
Leopoldo M; Lacivita E; De Giorgio P; Colabufo NA; Niso M; Berardi F; Perrone R
J Med Chem; 2006 Jan; 49(1):358-65. PubMed ID: 16392820
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.
Zuev D; Vrudhula VM; Michne JA; Dasgupta B; Pin SS; Huang XS; Wu D; Gao Q; Zhang J; Taber MT; Macor JE; Dubowchik GM
Bioorg Med Chem Lett; 2010 Jun; 20(12):3669-74. PubMed ID: 20471832
[TBL] [Abstract][Full Text] [Related]
39. Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction.
Qi LJ; Leung AT; Xiong Y; Marx KA; Abou-Samra AB
Biochemistry; 1997 Oct; 36(41):12442-8. PubMed ID: 9376348
[TBL] [Abstract][Full Text] [Related]
40. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S
Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
